Agios Pharmaceuticals Inc. (AGIO)
Market Closed
11 Jun, 20:00
$
28. 72
-0.16
-0.554%
Pre Market
$
+1.4 +4.8747% 30. 12
1.71B Market Cap
- P/E Ratio
- Div Yield
2.15M Volume
- Eps
$ 28.88
Previous Close Want to track AGIO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
AGIO closed today lower at $28.72, a decrease of -0.554% from yesterday's close, completing a monthly increase of 2.5714% or $0.72. Over the past 12 months, AGIO stock gained 5.3945%.
AGIO is not paying dividends to its shareholders.
The last earnings report, released on Apr 30, 2026, exceeded the consensus estimates by 1.795%. On average, the company has surpassed earnings expectations by 0.675%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate
Agios gains global rights to cevidoplenib for ITP, adding a late-stage rare hematology asset with up to $1B U.S. peak sales potential.
Zacks | 1 week ago
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcript
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcript
Seekingalpha | 1 week ago
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes
Agios discontinues development of tebapivat in lower-risk MDS after a phase IIb study misses efficacy goals, shifting focus to a phase II SCD program.
Zacks | 1 week ago
Agios Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Farallon Capital Farallon Capital Management LLC | 5.68M | $164.16M | $163.24M | -$919,278.48 | -0.56% |
 Anthony Scaramucci SkyBridge Capital II LLC | 2.72M | $75.32M | $78M | $2.69M | 3.56% |
| PF Phillip Fitzsimmons Hennion & Walsh Asset Management Inc. | 33,868 | $1.15M | $972,688.96 | -$178,067.3 | -15.47% |
| JC Joseph Castro Nuveen LLC | 722,348 | $22.86M | $20.75M | -$2.11M | -9.25% |
| BB Brian Baylis Bell Investment Advisors Inc. | 281 | $6,962.98 | $8,070.32 | $1,107.34 | 15.9% |
Agios Pharmaceuticals Inc. (AGIO) FAQ
What is the stock price today?
The current price is $28.72.
On which exchange is it traded?
Agios Pharmaceuticals Inc. is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is AGIO.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 1.71B.
Has Agios Pharmaceuticals Inc. ever had a stock split?
No, there has never been a stock split.
Agios Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Brian Goff CEO | NASDAQ (NGS) Exchange | 00847X104 CUSIP |
| US Country | 486 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Agios Pharmaceuticals, Inc., established in 2007 and based in Cambridge, Massachusetts, is a pioneering biopharmaceutical company. It focuses on the discovery and development of novel medications targeting cellular metabolism for the treatment of various diseases in the United States. By leveraging its expertise in the field of cellular metabolism, Agios is dedicated to advancing a diverse pipeline of therapeutic candidates aimed at addressing unmet medical needs.
Products and Services
- PYRUKYND (mitapivat): An innovative activator of both wild-type and mutant forms of the pyruvate kinase (PK) enzyme. This flagship product by Agios Pharmaceuticals, Inc. is designed for the treatment of hemolytic anemias, a group of disorders characterized by the premature destruction of red blood cells, leading to a deficiency in healthy red blood cells in the body. Mitapivat has shown promise in addressing the underlying metabolic dysfunctions found in these conditions.
- AG-946: Another PK activator in the company’s robust pipeline, AG-946 is currently being developed as a potential therapeutic option for patients with lower-risk myelodysplastic syndrome (MDS) and hemolytic anemias. By targeting PK, this compound aims to correct metabolic irregularities that contribute to the pathology of these disorders, offering hope for improved treatments.
- AG-181: A phenylalanine hydroxylase stabilizer being explored for its potential in treating phenylketonuria (PKU). PKU is a metabolic disorder caused by a deficiency of the enzyme phenylalanine hydroxylase, leading to high levels of phenylalanine in the blood, which can result in a variety of health problems. AG-181 aims to stabilize the enzyme, thereby reducing phenylalanine levels and mitigating the symptoms associated with PKU.
- siRNA Therapy for Polycythemia Vera: In its preclinical development stage, Agios is also investigating a small interfering RNA (siRNA) therapy targeting polycythemia vera, a rare blood disorder characterized by an overproduction of red blood cells. This innovative approach aims to silence specific gene expressions, offering a novel therapeutic pathway for managing this condition.
Contact Information
Address: 88 Sidney Street
Phone: 617 649 8600
Website: https://www.agios.com
